Edition:
United Kingdom

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

2.08USD
17 Aug 2018
Change (% chg)

$-0.07 (-3.26%)
Prev Close
$2.15
Open
$2.10
Day's High
$2.22
Day's Low
$2.04
Volume
50,152
Avg. Vol
27,161
52-wk High
$16.59
52-wk Low
$1.97

Select another date:

Fri, Aug 17 2018

Photo

Japan Mitsubishi Corp to acquire 25 percent stake in Bangladesh LNG terminal

SINGAPORE Japan's Mitsubishi Corp on Friday said it has agreed to acquire 25 percent of Bangladesh's Summit Liquefied Natural Gas (LNG) terminal and plans to help develop an offshore receiving site in the South Asian country.

Summit plunges 80 percent after muscle-wasting disorder drug fails

Britain's Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed a mid-stage study, wiping out nearly 80 percent of its market value.

Summit plunges 80 percent after muscle-wasting disorder drug fails

Britain's Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed a mid-stage study, wiping out nearly 80 percent of its market value.

UPDATE 2-Summit plunges 80 pct after muscle-wasting disorder drug fails

* Plummets 80 pct to touch record low (Adds details on trial, analyst comment)

Summit Therapeutics to stop developing muscle-wasting disorder drug

June 27 Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed to meet the goals of a mid-stage study.

BRIEF-Summit Therapeutics Files For Mixed Shelf Of Upto $225 Million

* SUMMIT THERAPEUTICS PLC FILES FOR MIXED SHELF OF UPTO $225 MILLION - SEC FILING Source http://bit.ly/2jXftRN Further company coverage:

BRIEF-Summit Therapeutics Says Proposed Placing To Raise Up To 15 Mln Stg

* ‍ANNOUNCES A PROPOSED PLACING TO RAISE UP TO £15.0 MILLION​

BRIEF-Summit's Infectious Diseases Technology Platform Yields Novel Antibiotics With Potential In Global Fight Against Gonorrhoea

* SUMMIT’S INFECTIOUS DISEASES TECHNOLOGY PLATFORM YIELDS NOVEL ANTIBIOTICS WITH POTENTIAL IN GLOBAL FIGHT AGAINST GONORRHOEA

BRIEF-Summit Expands Enrolment In Phaseout DMD Phase 2 Clinical Trial To Include Planned Additional Group

* SUMMIT EXPANDS ENROLMENT IN PHASEOUT DMD PHASE 2 CLINICAL TRIAL TO INCLUDE PLANNED ADDITIONAL GROUP Source text for Eikon: Further company coverage:

Select another date: